

Published Date:	Thursday 12th March, 2020	Publication:	The Hindu Business Line [Bangalore]
Journalist:	PTI	Page No:	4
MAV/CCM:	17,641/11.92	Circulation:	28,580

QUICKLY

Biocon wins patent case against Sanofi

New Delhi, March 11

Biotechnology major Biocon on Wednesday said a US court has invalidated a Sanofi patent on the insulin glargine device, thus removing a legal hurdle to commercialising Semglee co-developed with Mylan, in the US market. The US District Court of New Jersey found the device patent claims asserted by Sanofi against Biocon and Mylan's insulin glargine product 'not infringed' and 'invalid' for lack of written description, Biocon said in a filing to the BSE. As previously announced, Sanofi's formulation patents were earlier affirmed to be invalid by the Federal Circuit, it added. The new drug application (NDA) for Semglee is under active review by the USFDA, Biocon said. PTI